How Mazur was paid
$2.2M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Total |
|---|---|---|---|
| Leonard MazurChief Executive Officer and Executive Chairman | $166,250 | $2,035,000 | $2,201,250 |
| Myron HolubiakExecutive Vice Chairman | $450,000 | $825,000 | $1,275,000 |
| Myron CzuczmanChief Medical Officer | $225,000 | $770,000 | $995,000 |
What changed and why
- $2.2M$2,201,250 CEO total compensation in 2024, up from $661,875 in 2023.
- $2M$2,035,000 CEO option awards accounted for most of Leonard Mazur’s 2024 compensation.
- $450K$450,000 Myron Holubiak salary was unchanged from 2023, while option awards increased to $825,000.
- $225K$225,000 Myron Czuczman salary increased from $212,500 in 2023, while option awards increased to $770,000.
- $940K$940,000 quarterly shared-services fee is payable to Citius Pharmaceuticals under the services agreement.
- No director compensation was paid for the year ended September 30, 2024.
Other Citius Oncology proxy statements
- 2026 proxy statement
Leonard Mazur paid $3.8M (+72% on the year).
Filed Aug 26, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.